Contact this trialFirst, we need to learn more about you.
Monoclonal Antibodies
Lenalidomide + Dinutuximab +/- Isotretinoin for Neuroblastoma
Recruiting1 awardPhase 1
Chapel Hill, North Carolina
This trial studies the best dose and side effects of a combination of three drugs for young patients with difficult-to-treat neuroblastoma. The drugs work together to kill or stop the growth of cancer cells, with one drug specifically targeting the cancer cells. IBL-302 has shown promise in enhancing the effects of common treatments like cisplatin, doxorubicin, and etoposide in neuroblastoma treatment.
Fill-in a few details and create your profileSave answers to your profile & unlock recommendations.
We will keep your details privateWe won't share unless you give us permission. By completing this form you agree to our privacy policy and terms of service
Get in touch with the study teamWe’ll send your responses to the study team and help you to setup your first screening. This is not the start of informed consent. Screening happens between you and the trial.
By clicking start, you agree to our
terms of service